Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.61 |
| ▸ | CTSK | P43235 | 5/20 | 0.61 |
| ▸ | CTSB | P07858 | 3/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | APP | P05067 | 3/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4859984 | 1.00 | CTSS (0.61) | CTSSCTSKCTSBATMAAK1 | |
| SCHEMBL5063200 | 0.88 | CTSS (0.62) | CTSSCTSKCTSBATMAAK1 | |
| SCHEMBL30597876 | 0.88 | CTSS (0.62) | CTSSCTSKCTSBATMAAK1 | |
| SCHEMBL4860365 | 0.88 | CTSS (0.62) | CTSSCTSKCTSBATMAAK1 | |
| SCHEMBL4598553 | 0.87 | CTSS (0.58) | CTSSCTSKCTSBATMAAK1 | |
| SCHEMBL6835384 | 0.86 | ATM (0.54) | CTSSCTSKCTSBATMCTSL | |
| SCHEMBL6835385 | 0.86 | ATM (0.54) | CTSSCTSKCTSBATMCTSL | |
| SCHEMBL14870431 | 0.85 | ATM (0.53) | CTSSCTSKCTSBATMCTSL | |
| SCHEMBL13905628 | 0.85 | CTSL (0.61) | CTSSCTSKCTSBATMCTSL | |
| SCHEMBL28652921 | 0.85 | ATM (0.53) | CTSSCTSKCTSBATMCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470696-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470713-B2 | Imidazole based kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-7312215-B2 | Benzimidazole C-2 heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-7232826-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-19 | — | — | US | disclosed |
| US-20070135443-A1 | NOVEL TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-7223757-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-29 | — | — | US | disclosed |
| US-7189716-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-13 | — | — | US | disclosed |
| US-7081454-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB CO. (US) | 2006-07-25 | — | — | US | disclosed |
| US-20060079518-A1 | Novel tyrosine kinase inhibitors | WITTMAN MARK D | 2006-04-13 | — | — | US | disclosed |
| US-20050187218-A1 | Imidazole based kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-25 | — | — | US | disclosed |
| EP-1545529-A2 | NOVEL TYROSINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20050054655-A1 | Benzimidazole C-2 heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
| US-20040180897-A1 | Novel tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-16 | — | — | US | disclosed |
| US-20040092514-A1 | Novel tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-13 | — | — | US | disclosed |
| WO-2004030620-A2 | NOVEL TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-15 | — | — | WO | disclosed |
| US-20040044203-A1 | Novel tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180897-A1 | Novel tyrosine kinase inhibitors | ABL1, ROS1, YES1 | CTSS 3168/4885CTSK 1189/4885CTSB 3109/4885 |
| US-20050054655-A1 | Benzimidazole C-2 heterocycles as kinase inhibitors | CDK2, ERBB2, ABL1 | CTSS 1657/4885CTSK 584/4885CTSB 2195/4885 |
| US-20040044203-A1 | Novel tyrosine kinase inhibitors | ABL1, YES1, FER | CTSS 2718/4885CTSK 931/4885CTSB 2861/4885 |
| US-20050187218-A1 | Imidazole based kinase inhibitors | MAP3K19, MAP3K1, ABL1 | CTSS 3098/4885CTSK 793/4885CTSB 2098/4885 |
| US-20040092514-A1 | Novel tyrosine kinase inhibitors | ABL1, ERBB2, ROS1 | CTSS 2408/4885CTSK 909/4885CTSB 2220/4885 |
| US-20060079518-A1 | Novel tyrosine kinase inhibitors | ABL1, FER, ERBB2 | CTSS 2531/4885CTSK 839/4885CTSB 2715/4885 |
| US-20070135443-A1 | NOVEL TYROSINE KINASE INHIBITORS | ABL1, ERBB2, ROS1 | CTSS 2876/4885CTSK 1048/4885CTSB 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.